Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer

Li, Zhihong; Zhang, Hong; Yang, Zhiyong; Wen, Guoqiang; Cui, Youbing; Shao, Guoguang

doi:10.1177/0300060513497560

Cited by 44 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At present, Among miRNAs studies, miR-210 has become one of the most widely studied one in cancer, which was reported to be upregulated in various types of cancers (32,33) and has played an important role in tumorigenesis. This result was consistent with previous findings in which miR-210 levels were increased in lung cancer patients (34)(35)(36)(37). MiR-210 levels expression also was a prognostic factor for survival of lung cancer patients (38).…”

Section: Discussionsupporting

confidence: 93%

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

et al. 2016

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 93%

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

et al. 2016

View full text Add to dashboard Cite

“…In total, 28 eligible records and references were included in the analysis: GEO datasets (n = 24), TCGA (n = 1), in-house RT-qPCR (n = 1), and qualified references (n = 2 [29, 30]). Their characteristics are summarized in Table 1.…”

Section: Resultsmentioning

confidence: 99%

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

Cen

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Since the function of microRNA (miR)-210 in non-small cell lung cancer (NSCLC) remains unclear, we aimed to explore the clinical significance of miR-210 in NSCLC. Methods: NSCLC-related data from 1673 samples on Gene Expression Omnibus and 1090 samples on The Cancer Genome Atlas were obtained and analyzed. The expression level of miR-210 was validated via real-time quantitative PCR analysis with 125 paired clinical samples. A meta-analysis was performed to generate a comprehensive understanding of miR-210 expression and its clinical significance in NSCLC. In addition, bioinformatics analysis was also conducted to reveal the potential underlying mechanism of miR-210 action in NSCLC. Results: miR-210 expression was consistently elevated in NSCLC solid tissue samples. However, its expression was controversial in easily obtained body fluids (i.e., blood, plasma, and serum). Moreover, an overall pooled meta-analysis implied a comparatively higher level of miR-210 expression in NSCLC cancerous tissue than in normal control tissue (P < 0.001). In addition, a meta-analysis of outcome revealed a significant diagnostic capacity of miR-210 in NSCLC by detecting its expression in serum and sputum (area under the summary receiver operating characteristic curve 0.82 and 0.81, respectively). miR-210 overexpression was associated with poor progression-free survival (PFS) in NSCLC and was negatively related to overall survival and disease-free survival. Bioinformatic gene enrichment and annotation analyses showed that the target genes of miR-210 were greatly enriched in cell adhesion and plasma membrane, and three pathways were considered to be the main functional circuits of miR-210: renin secretion, the cGMP-PKG signaling pathway, and cell adhesion molecules. Conclusion: In NSCLC, miR-210 expression was elevated and overexpression indicated poor PFS. Expression level of miR-210 in serum and sputum showed significant diagnostic value for NSCLC.

show abstract

“…For example, miR-221 has been found to be significantly increased in the plasma of patients with colorectal cancer (CRC) and gastric cancer (GC), among others2122. The levels of serum miR-210 are markedly elevated in patients with non-small-cell lung cancer and prostate cancer2324. In the case of miR-1233 and miR-508-3p, while the two miRNAs have not been found to be altered in patients with other cancers, their clinical performance has not yet been independently evaluated for the early detection of RCC1316.…”

Section: Discussionmentioning

confidence: 99%

A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma

Wang¹,

Lü

et al. 2015

Sci Rep

120

114

View full text Add to dashboard Cite

Circulating microRNAs (miRNAs) are emerging as clinically useful tools for cancer detection; however, little is known about their early diagnostic impact on RCC. The levels of 754 serum miRNAs were initially determined using a TaqMan Low Density Array in two pooled samples from 25 RCC and 25 noncancer controls. Markedly dysregulated miRNAs in RCC cases were subsequently validated individually by qRT-PCR in another 107 patients and 107 controls arranged in two sets. The serum levels of miR-193a-3p, miR-362 and miR-572 were significantly increased whereas the levels of miR-28-5p and miR-378 were markedly decreased in patients with RCC, even in those with stage I disease, compared with the noncancer controls (P < 0.01). The areas under the ROC curve (AUCs) for the 5 combined miRNAs were 0.807 (95% CI, 0.687–0.928) and 0.796 (95% CI, 0.724–0.867) for the training set and the validation set, respectively. Furthermore, the panel enabled the differentiation of stage I RCC from controls with AUC of 0.807 (95% CI, 0.731–0.871), a sensitivity of 80% and a specificity of 71%. This panel of 5 serum miRNA may have the potential to be used clinically as an auxiliary diagnostic tool for the early detection of RCC.

show abstract

Prognostic significance of serum microRNA-210 levels in nonsmall-cell lung cancer

Abstract: These findings suggest that serum miR-210 levels might be a novel diagnostic and prognostic marker of NSCLC.

Cited by 44 publications

References 28 publications

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

Role of plasma MicroRNAs in the early diagnosis of non-small-cell lung cancers: a case-control study

Clinical Significance of miR-210 and its Prospective Signaling Pathways in Non-Small Cell Lung Cancer: Evidence from Gene Expression Omnibus and the Cancer Genome Atlas Data Mining with 2763 Samples and Validation via Real-Time Quantitative PCR

A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma

Contact Info

Product

Resources

About